Abstract: The present invention provides an oral pharmaceutical composition for the treatment of premature ejaculation, and the composition provides the effective and excellent treatment of premature ejaculation as well as reduced side effects like nausea, vomiting, drowsiness, sedation effect, awakening effect, and weight-loss etc.

Abstract: A hybrid porous structure may include a base template and an ionic polymer coating layer within the base template. The structural framework of the base template itself is non-porous. The base template fills the gaps among a plurality of imaginary spherical bodies stacked in three-dimensions as an imaginary stack. The ionic polymer coating layer is laminated on an inner surface of the base template inside the imaginary spherical bodies. The imaginary spherical bodies may have a pore in the center which is not occupied by the ionic polymer coating layer. The hybrid porous structure may include a plurality of necks, which are openings formed in a contact part where adjacent imaginary spherical bodies contact each other. The necks may be interconnected to the pores located in the center part of the imaginary spherical bodies.

Abstract: A hybrid porous structured material may include a porous region (that forms a nanopore structure) and a non-porous region. The porous region may form a stacked structure where a plurality of spherical bodies are stacked so as to contact each other in three dimensions. The non-porous region may form a structure that fills a gap between the plurality of spherical bodies of the porous region.

Abstract: Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.

Abstract: The present invention reports a defect that has not been reported, and discloses a defect-controlled silicon ingot, a defect-controlled wafer, and a process and apparatus for manufacturing the same. The new defect is a crystal defect generated when a screw dislocation caused by a HMCZ (Horizontal Magnetic Czochralski) method applying a strong horizontal magnetic field develops into a jogged screw dislocation and propagates to form a cross slip during thermal process wherein a crystal is cooled. The present invention changes the shape and structure of an upper heat shield structure arranged between a heater and an ingot above a silicon melt, and controls initial conditions or operation conditions of a silicon single crystalline ingot growth process to reduce a screw dislocation caused by a strong horizontal magnetic field and prevent the screw dislocation from propagating into a cross slip.

Abstract: The present invention reports a defect that has not been reported, and discloses a defect-controlled silicon ingot, a defect-controlled wafer, and a process and apparatus for manufacturing the same. The new defect is a crystal defect generated when a screw dislocation caused by a HMCZ (Horizontal Magnetic Czochralski) method applying a strong horizontal magnetic field develops into a jogged screw dislocation and propagates to form a cross slip during thermal process wherein a crystal is cooled. The present invention changes the shape and structure of an upper heat shield structure arranged between a heater and an ingot above a silicon melt, and controls initial conditions or operation conditions of a silicon single crystalline ingot growth process to reduce a screw dislocation caused by a strong horizontal magnetic field and prevent the screw dislocation from propagating into a cross slip.

Abstract: The present invention reports a defect that has not been reported, and discloses a defect-controlled silicon ingot, a defect-controlled wafer, and a process and apparatus for manufacturing the same. The new defect is a crystal defect generated when a screw dislocation caused by a HMCZ (Horizontal Magnetic Czochralski) method applying a strong horizontal magnetic field develops into a jogged screw dislocation and propagates to form a cross slip during thermal process wherein a crystal is cooled. The present invention changes the shape and structure of an upper heat shield structure arranged between a heater and an ingot above a silicon melt, and controls initial conditions or operation conditions of a silicon single crystalline ingot growth process to reduce a screw dislocation caused by a strong horizontal magnetic field and prevent the screw dislocation from propagating into a cross slip.

Abstract: The present invention reports a defect that has not been reported, and discloses a defect-controlled silicon ingot, a defect-controlled wafer, and a process and apparatus for manufacturing the same. The new defect is a crystal defect generated when a screw dislocation caused by a HMCZ (Horizontal Magnetic Czochralski) method applying a strong horizontal magnetic field develops into a jogged screw dislocation and propagates to form a cross slip during thermal process wherein a crystal is cooled. The present invention changes the shape and structure of an upper heat shield structure arranged between a heater and an ingot above a silicon melt, and controls initial conditions or operation conditions of a silicon single crystalline ingot growth process to reduce a screw dislocation caused by a strong horizontal magnetic field and prevent the screw dislocation from propagating into a cross slip.

Abstract: A method of communicating on a mobile communication terminal. The method includes inputting category information identifying a category of contents, providing a list of content information on a server corresponding to the input category information, wherein a content information indicates a portion of a content that the mobile communication terminal can connect to, selecting at least one of the list of content information, and connecting to the content corresponding to said at least one of the selected content information.

Abstract: A semiconductor memory device includes a first memory block, a second memory block, and a signal controller. The first memory block is configured to generate a first blocking signal, a second blocking signal, and a first enable signal in response to a row address, and to block and enable wordlines of the memory block in response to the first blocking signal and the first enable signal, respectively. The second memory block is configured to generate a third blocking signal, a fourth blocking signal, and a second enable signal in response to the row address, and to block and enable wordlines of the second memory block in response to the third blocking signal and the second enable signal, respectively. The signal controller is connected between the first memory block and the second memory block and is configured to enable the third blocking signal when the second blocking signal is enabled, and to enable the first blocking signal when the fourth blocking signal is enabled.

Abstract: An anisotropic conductive adhesive composite and film includes a binder and conductive particles dispersed in the binder. The conductive particles include a copper core particle and a metal coating layer coated on a surface of the corresponding copper core particle.

Abstract: A method of changing a serving Base Station (BS) in a mobile communication system, and a mobile communication system for implementing the method, are provided.

Abstract: The present invention provides an oral pharmaceutical composition for the treatment of premature ejaculation, and the composition provides the effective and excellent treatment of premature ejaculation as well as reduced side effects like nausea, vomiting, drowsiness, sedation effect, awakening effect, and weight-loss etc.

Abstract: The present invention relates to a United Reflection Lights with Light-Emitting Diode (LED). In accordance with the present invention, the United Reflection Lights with LED consists of a housing; LED light sources which are installed with an inclination angle to the opposite inside wall of the housing and emit rays in forms of dots to the inside of the housing; and a reflecting plate which, placed in the bottom of the housing, reflect asymmetrically the incident rays originated from the above LED light sources with a number of triangle-shaped projecting parts and act as an indirect lighting device as it lets each of the above mentioned asymmetrically reflected rays combine and go to an intended direction in the form of a plane light source. The surface of the reflecting plate is covered with high polished synthetic resin.

Abstract: The present invention relates to an energy concentration device of united reflection with multilevel solar cell array comprising: a housing and solar cell parts, which are multilevel arrayed inside or outside the housing in such a way that the part of collected sunlight is absorbed in each level and then the rest of unabsorbed sunlight is absorbed overall from multilevel of solar cells in the iterating process of reflecting sunlight on the surfaces of solar cell parts. By the present invention, if an energy concentration device of united reflection with multilevel solar cell array is attached to the solar concentration device and so on, it is possible to attach to both fixed type and movable type. In the process of reflecting and absorbing sunlight continuously to maximise sunlight availability, solar cell parts are arrayed multilevel to improve the collecting efficiency.

Abstract: A sustained release composition for oral administration of niacin, comprising niacin; a carrier for sustained release composed of a hydrophilic polymer and a hydrophobic polymer; and a pharmaceutically acceptable additive, the hydrophilic polymer being a polyethylene oxide and a natural gum, is capable of maintaining a constant release rate of niacin.

Abstract: A semiconductor memory device includes a first memory block, a second memory block, and a signal controller. The first memory block is configured to generate a first blocking signal, a second blocking signal, and a first enable signal in response to a row address, and to block and enable wordlines of the memory block in response to the first blocking signal and the first enable signal, respectively. The second memory block is configured to generate a third blocking signal, a fourth blocking signal, and a second enable signal in response to the row address, and to block and enable wordlines of the second memory block in response to the third blocking signal and the second enable signal, respectively. The signal controller is connected between the first memory block and the second memory block and is configured to enable the third blocking signal when the second blocking signal is enabled, and to enable the first blocking signal when the fourth blocking signal is enabled.

Abstract: An apparatus for processing an eyeglass lens which is capable of forming a hole or various shapes on an eyeglass lens is disclosed. The apparatus includes a pair of lens fixing shafts for clamping a lens; a carriage which supports and moves the lens fixing shafts; a lens rotation motor for rotating the lens fixing shafts; and a drilling part for forming a hole on the lens, wherein the drilling part includes: a drill head having a drill to which a drill bit is fixed; a drill head mover which is connected with the drill head and moves the drill head straightly; and a fixing block which supports and fixes the drill head mover on the apparatus for processing an eyeglass lens.

Abstract: A controlled release combination formulation for oral administration comprising a) a controlled release portion containing metformin or a pharmaceutically acceptable salt thereof as an active ingredient, and a combination of a polyethylene oxide and a natural gum as a carrier for controlled release; and b) a rapid-release portion containing a sulfonylurea-based medicine for treating diabetes as an active ingredient coated on the controlled release portion is useful for the treatment of diabetes, for it is capable of maintaining an effective concentration of the medicines in blood at a constant level.

Abstract: The present invention reports a defect that has not been reported, and discloses a defect-controlled silicon ingot, a defect-controlled wafer, and a process and apparatus for manufacturing the same. The new defect is a crystal defect generated when a screw dislocation caused by a HMCZ (Horizontal Magnetic Czochralski) method applying a strong horizontal magnetic field develops into a jogged screw dislocation and propagates to form a cross slip during thermal process wherein a crystal is cooled. The present invention changes the shape and structure of an upper heat shield structure arranged between a heater and an ingot above a silicon melt, and controls initial conditions or operation conditions of a silicon single crystalline ingot growth process to reduce a screw dislocation caused by a strong horizontal magnetic field and prevent the screw dislocation from propagating into a cross slip.